Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease

References

• Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age, distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med. 1995; 155: 469–73
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Eur Heart J. 2001; 22: 1852–1923
   PubMed Web of Science ®Google Scholar
• Gajewski J, Singer RB. Mortality in an insured population with atrial fibrillation. JAMA. 1981; 245: 1540–4
   PubMed Web of Science ®Google Scholar
• Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation; the Framingham Study. N Engl J Med. 1982; 306: 1018–22
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998; 98: 946–52
   PubMed Web of Science ®Google Scholar
• Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation; incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med. 1995; 98: 476–84
   PubMed Web of Science ®Google Scholar
• Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997; 30: 406–13
   PubMed Web of Science ®Google Scholar
• Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: Prevalence and outcomes. Circulation. 2000; 101: 969–74
   PubMed Web of Science ®Google Scholar
• Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: The OPTIMAAL experience. Eur Heart J. 2005; 26: 350–6
   PubMed Web of Science ®Google Scholar
• Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, et al. Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003; 139: 1009–17
   PubMed Web of Science ®Google Scholar
• O'Donnell M, Agnelli G, Weitz JI. Emerging therapies for stroke prevention in atrial fibrillation. Eur Heart J 2005; 7(Suppl C): C19–C27
   Google Scholar
• Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke. 2003; 34: 2741–8
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Tsang TSM, Barnes ME, Seward JB. The changing epidemiology of non-valvular atrial fibrillation: The role of novel risk factors. Eur Heart J 2005; 7(Suppl C): C5–C11
   Google Scholar
• Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen F, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet. 2004; 364: 849–57
   PubMed Web of Science ®Google Scholar
• Lubsen J, Poole-Wilson PA, Pocock SJ, van Dalen FJ, Baumann J, Kirwan BA, et al. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Eur Heart J 1998; 19(Suppl I): 20–32
   Google Scholar
• Otterstad JE, Froeland G, St. John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997; 18: 507–13
   PubMed Web of Science ®Google Scholar
• Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias. Stat Med. 1984; 3: 35–44
   PubMed Web of Science ®Google Scholar
• The national heart, lung and blood institute working group on Atrial Fibrillation. Atrial fibrillation: Current understandings and research imperatives. J Am Coll Cardiol. 1993; 22: 1830–4
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999; 100: 376–80
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm AJ. Clinical trends in atrial fibrillation at the turn of the millennium. J Intern Med. 2001; 250: 369–72
   PubMed Web of Science ®Google Scholar
• Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003; 27: 443–9
   PubMed Web of Science ®Google Scholar
• Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insights from the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation. 2003; 107: 2926–31
   PubMed Web of Science ®Google Scholar